The University of Southampton
University of Southampton Institutional Repository

A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS

A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS
A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS

Background: neoadjuvant chemotherapy (NAC) allows earlier treatment of rectal cancer micro-metastases but is not standard of care. There are currently no biomarkers predicting long-term progression-free survival (PFS) benefit from NAC.

Patients and methods: in this single arm phase II trial, patients with non-metastatic magnetic resonance imaging (MRI)-defined operable rectal adenocarcinoma at high risk of post-operative metastatic recurrence, received 8 weeks of oxaliplatin/fluorouracil NAC then short-course preoperative radiotherapy (SCPRT) before immediate surgery. Sixteen weeks of post-operative adjuvant chemotherapy (AC) was planned. A pelvic MRI was performed at week 9 immediately post-NAC, before SCPRT. The primary end point was feasibility assessed by completion of protocol treatment up to and including surgery. Secondary endpoints included compliance, toxicity, downstaging efficacy, and PFS.

Results: in total 60 patients were recruited May 2012–June 2014. In total 57 patients completed protocol treatment, meeting the primary endpoint. Compliance with NAC was much better than AC: Comparing NAC vs. AC, the median percentage dose intensity for fluoropyrimidine was 100% vs. 63% and for oxaliplatin 100% vs. 45%. Treatment-related toxicity was acceptable with no treatment-related deaths. Post-NAC MRI showed 44 tumours (73%) were T-downstaged and 22 (37%) had excellent MRI tumour regression grade (mrTRG 1–2). Median follow-up was 27 months with 2-year PFS of 86.2% (10 events). On exploratory analysis, post-NAC mrTRG predicted PFS with no event among those with excellent regression.

Conclusion: the regimen was well tolerated with effective downstaging and encouraging PFS. mrTRG response to NAC may be a new prognostic factor for long-term PFS, but needs validation in larger studies.

0007-0920
697-706
Gollins, Simon
ae092a24-b3fb-4d95-b5af-802a14bd79f8
West, Nicholas
8cee9b96-bc23-4b8e-8878-de92c122afe6
Sebag-Montefiore, David
7cd6f558-4265-4adb-b8dd-771f47ab8343
Susnerwala, Shabbir
3b9786bb-f928-43b2-8046-a9b92610253e
Falk, Stephen
6bda4f5d-d5b0-4558-89d3-9e32cacf202a
Brown, Nick
3b180870-5116-4d93-9d28-5a0b5e4b04d6
Saunders, Mark
80628c20-7977-476f-8eb0-eb729fd96296
Quirke, Philip
e0a608ee-6f6a-4972-b7ff-2e94780fcc56
Ray, Ruby
6a82843d-17d5-4cea-95bd-3680df255324
Parsons, Philip
48a6af49-b049-446e-86a9-d07395f14ee9
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Maughan, Tim
9f5b1ca4-9ed7-4100-bf04-c4026e4b5395
Adams, Richard
3325b0a6-86f6-4ba4-a1ec-972b73083599
Hurt, Chris
bf8b37a0-8f08-4b47-b3f3-6fc65f7ab87f
et al.
Gollins, Simon
ae092a24-b3fb-4d95-b5af-802a14bd79f8
West, Nicholas
8cee9b96-bc23-4b8e-8878-de92c122afe6
Sebag-Montefiore, David
7cd6f558-4265-4adb-b8dd-771f47ab8343
Susnerwala, Shabbir
3b9786bb-f928-43b2-8046-a9b92610253e
Falk, Stephen
6bda4f5d-d5b0-4558-89d3-9e32cacf202a
Brown, Nick
3b180870-5116-4d93-9d28-5a0b5e4b04d6
Saunders, Mark
80628c20-7977-476f-8eb0-eb729fd96296
Quirke, Philip
e0a608ee-6f6a-4972-b7ff-2e94780fcc56
Ray, Ruby
6a82843d-17d5-4cea-95bd-3680df255324
Parsons, Philip
48a6af49-b049-446e-86a9-d07395f14ee9
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Maughan, Tim
9f5b1ca4-9ed7-4100-bf04-c4026e4b5395
Adams, Richard
3325b0a6-86f6-4ba4-a1ec-972b73083599
Hurt, Chris
bf8b37a0-8f08-4b47-b3f3-6fc65f7ab87f

Gollins, Simon, West, Nicholas and Sebag-Montefiore, David , et al. (2018) A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. British Journal of Cancer, 119, 697-706. (doi:10.1038/s41416-018-0209-4).

Record type: Article

Abstract

Background: neoadjuvant chemotherapy (NAC) allows earlier treatment of rectal cancer micro-metastases but is not standard of care. There are currently no biomarkers predicting long-term progression-free survival (PFS) benefit from NAC.

Patients and methods: in this single arm phase II trial, patients with non-metastatic magnetic resonance imaging (MRI)-defined operable rectal adenocarcinoma at high risk of post-operative metastatic recurrence, received 8 weeks of oxaliplatin/fluorouracil NAC then short-course preoperative radiotherapy (SCPRT) before immediate surgery. Sixteen weeks of post-operative adjuvant chemotherapy (AC) was planned. A pelvic MRI was performed at week 9 immediately post-NAC, before SCPRT. The primary end point was feasibility assessed by completion of protocol treatment up to and including surgery. Secondary endpoints included compliance, toxicity, downstaging efficacy, and PFS.

Results: in total 60 patients were recruited May 2012–June 2014. In total 57 patients completed protocol treatment, meeting the primary endpoint. Compliance with NAC was much better than AC: Comparing NAC vs. AC, the median percentage dose intensity for fluoropyrimidine was 100% vs. 63% and for oxaliplatin 100% vs. 45%. Treatment-related toxicity was acceptable with no treatment-related deaths. Post-NAC MRI showed 44 tumours (73%) were T-downstaged and 22 (37%) had excellent MRI tumour regression grade (mrTRG 1–2). Median follow-up was 27 months with 2-year PFS of 86.2% (10 events). On exploratory analysis, post-NAC mrTRG predicted PFS with no event among those with excellent regression.

Conclusion: the regimen was well tolerated with effective downstaging and encouraging PFS. mrTRG response to NAC may be a new prognostic factor for long-term PFS, but needs validation in larger studies.

Text
s41416-018-0209-4 - Version of Record
Available under License Creative Commons Attribution.
Download (825kB)

More information

Accepted/In Press date: 9 July 2018
e-pub ahead of print date: 17 August 2018
Published date: September 2018

Identifiers

Local EPrints ID: 424196
URI: http://eprints.soton.ac.uk/id/eprint/424196
ISSN: 0007-0920
PURE UUID: 0a812083-b723-43d4-9d90-843574aba52b
ORCID for Gareth Griffiths: ORCID iD orcid.org/0000-0002-9579-8021
ORCID for Chris Hurt: ORCID iD orcid.org/0000-0003-1206-8355

Catalogue record

Date deposited: 05 Oct 2018 11:34
Last modified: 21 Mar 2024 03:14

Export record

Altmetrics

Contributors

Author: Simon Gollins
Author: Nicholas West
Author: David Sebag-Montefiore
Author: Shabbir Susnerwala
Author: Stephen Falk
Author: Nick Brown
Author: Mark Saunders
Author: Philip Quirke
Author: Ruby Ray
Author: Philip Parsons
Author: Tim Maughan
Author: Richard Adams
Author: Chris Hurt ORCID iD
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×